Ono Pharma USA, Inc.
Clinical Trials
21
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
- Conditions
- Irritable Bowel Syndrome (IBS)
- Interventions
- Drug: Placebo comparator
- First Posted Date
- 2013-06-26
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- Ono Pharma USA Inc
- Target Recruit Count
- 39
- Registration Number
- NCT01887002
- Locations
- 🇺🇸
Boston Clinical Site, Boston, Massachusetts, United States
🇺🇸St. Louis Clinical Site, St. Louis, Missouri, United States
🇺🇸Chapel Hill Clinical Site, Chapel Hill, North Carolina, United States
A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
- Conditions
- Irritable Bowel Syndrome (IBS)
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- Ono Pharma USA Inc
- Target Recruit Count
- 200
- Registration Number
- NCT01844180
- Locations
- 🇺🇸
Anniston Clinical Site, Anniston, Alabama, United States
🇺🇸Goodyear Clinical Site, Goodyear, Arizona, United States
🇺🇸Tucson Clinical Site, Tucson, Arizona, United States
An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment
- Conditions
- HealthyHepatic Impairment
- Interventions
- Drug: ONO-2745 /CNS 7056
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- Ono Pharma USA Inc
- Target Recruit Count
- 20
- Registration Number
- NCT01790607
- Locations
- 🇺🇸
Anaheim Clinical Site, Anaheim, California, United States
🇺🇸Orlando Clinical Site, Orlando, Florida, United States
🇺🇸South Miami Clinical Site, South Miami, Florida, United States
Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma
- Conditions
- Ocular Hypertension (OHT)Mild Open Angle-glaucoma (OAG)
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-08-22
- Last Posted Date
- 2013-06-03
- Lead Sponsor
- Ono Pharma USA Inc
- Target Recruit Count
- 60
- Registration Number
- NCT01670266
- Locations
- 🇺🇸
Costa Mesa Clinical Site, Costa Mesa, California, United States
🇺🇸Newport Beach (satellite site), Newport Beach, California, United States
🇺🇸Santa Ana (satellite site), Santa Ana, California, United States
ONO-2952 Single-dose PET Study in Healthy Adult Subjects
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2013-06-03
- Lead Sponsor
- Ono Pharma USA Inc
- Target Recruit Count
- 16
- Registration Number
- NCT01613703
- Locations
- 🇺🇸
Pittsburgh Clinical Site, Pittsburgh, Pennsylvania, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next